Business Standard

Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

Diabetes drug, MEDICINE, PHARMA
Premium

The National Pharmaceutical Pricing Authority (NPPA) has capped the prices of these two drugs in the range of Rs 16-25 per tablet.

Sohini Das Mumbai
With more patients shifting to new gliptins (a category of diabetes drugs) as they go off-patent, the national pharma pricing regulator has moved quickly to cap prices of two diabetes molecules Sitagliptin and Linagliptin and their combinations.
 
Around nine per cent of India’s 1.4 billion population has Type-2 diabetes, and this has crossed 11 per cent in few urban pockets. It is thus estimated that 100 million people in India have diabetes, but about half the Type-2 diabetes cases go undiagnosed.
 
Government sources reveal that the regulator is keeping a keen watch on diabetes drug prices, and also

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Aug 27 2022 | 1:06 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com